



I hereby certify that the correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,

Washington, D.C. 20231 on May 16, 2000

Frank C Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

AMENDMENT UNDER
37 CFR 1.825(a) THROUGH (c)
Examining Group 1644
Patent Application
Docket No. SPO-103
Serial No. 09/142,524

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : M. DiBrino, Ph.D.
Art Unit : 1644
Applicant(s) : Toshio Sone, Akinori Kume, Kazuo Dairiki, Akiko Iwama, Kohsuke Kino
Serial No. : 09/142,524
Filed : September 9, 1998
For : Peptide-based Immunotherapeutic Agent for Treating Allergic Diseases

Box SEQUENCE

Assistant Commissioner for Patents

Washington, D.C. 20231

AMENDMENT UNDER 37 CFR 1.825(a) THROUGH (c)

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures received in the above-identified patent application, please amend the subject application as follows:

In the Specification

Please replace pages 1-3 of the sequence listing with the accompanying sequence listing as new pages 1-5.